Article
Applied Clinical Trials
TARGET PharmaSolutions, Inc., a company focused on real-world evidence, launched its latest large-scale observational study, TARGET-DERM. The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema). and vitiligo (loss of skin pigment).
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.